Treatment is restricted to patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost- effectiveness of brodalumab. It is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Separately, NICE had also issued guidance recommending brodalumab as an option for treating plaque psoriasis in adults, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.